Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2095703 | 0.86 | ALDH1A1 (0.41) | ALDH1A1POLBLMNAKMT2AMEN1 | |
| SCHEMBL2098763 | 0.76 | POLB (0.36) | ALDH1A1POLBLMNAKMT2AMEN1 | |
| SCHEMBL2054714 | 0.74 | ALDH1A1 (0.41) | ALDH1A1POLBLMNAKMT2AMEN1 | |
| SCHEMBL2054703 | 0.74 | ALDH1A1 (0.41) | ALDH1A1POLBLMNAKMT2AMEN1 | |
| SCHEMBL2054699 | 0.67 | ALDH1A1 (0.38) | ALDH1A1POLBLMNATSHRL3MBTL1 | |
| SCHEMBL2054710 | 0.66 | ALDH1A1 (0.41) | ALDH1A1POLBKMT2AMEN1TSHR | |
| SCHEMBL13528425 | 0.61 | ALDH1A1 (0.60) | ALDH1A1POLBLMNAMAPTSMN1; SMN2 | |
| SCHEMBL2054715 | 0.60 | CRBN (0.56) | ALDH1A1POLBLMNAKMT2AMEN1 | |
| SCHEMBL19764001 | 0.57 | RAB9A (0.42) | ALDH1A1LMNAKMT2AMEN1L3MBTL1 | |
| SCHEMBL8363511 | 0.55 | POLB (0.60) | ALDH1A1POLBLMNATSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163956-B2 | Inhibitors of GLYT1 transporters | MERCK SHARP & DOHME CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163956-B2 | Inhibitors of GLYT1 transporters | MERCK SHARP & DOHME CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163956-B2 | Inhibitors of GLYT1 transporters | MERCK SHARP & DOHME CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090286765-A1 | Therapeutic Agents | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090286765-A1 | Therapeutic Agents | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090286765-A1 | Therapeutic Agents | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| EP-1899294-A1 | THERAPEUTIC AGENTS | Merck Sharp & Dohme Limited (GB) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006134341-A1 | THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286765-A1 | Therapeutic Agents | GRIA1, GRIN1, GLRA1 | ALDH1A1 652/4885POLB 4418/4885LMNA 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.